

## **Quantum Genomics publishes its results for the 2023 financial year.**

### **The merger with ExactCure, which marks the strategic redeployment of the company and will be submitted for a shareholder vote on April 24.**

**Quantum Genomics (Euronext Growth—FR0011648971 - ALQGC)** publishes its financial results for the 2023 financial year today.

The Board of Directors approved the annual accounts, which met on March 12, 2024. The audit procedures have been carried out, and the audit report relating to the account certification is available on the Company's website. The annual financial report for the financial year ending December 31, 2023, is available on the Company's website: <https://quantum-genomics.com/en/>, "investors" section.

On the occasion of the publication of the annual results of Quantum Genomics, Jean-Philippe Milon, its Chairman and CEO, declared:

*"2023 was a year of refoundation for Quantum Genomics. We worked to preserve our cash flow by restructuring our workforce and supplier debt so that we could launch a new, valuable, and sustainable business project. Thanks to our unfailing will and the renewed confidence of our shareholders, first and foremost, Otium Capital, we are approaching 2024 with confidence.*

*After an in-depth examination of several opportunities, we identified a unifying and value-creating project in e-health developed by ExactCure. The merger with this company will give Quantum Genomics a new start by responding to the major Public Health challenge of the proper use of medicines and bringing significant and lasting changes to Health.*

*For our company, the year 2024 will truly begin on April 24, the date of the Annual Ordinary and Extraordinary General Meeting, which will be called to decide on the merger that we are considering with ExactCure. I invite our shareholders to participate in this General Meeting by voting massively in favor of this project to make their voices heard and to give our company a new ambition. »*

#### **A preserved financial situation to redeploy the company's activity**

The results for the 2023 financial year reflect the cessation of the development of firibastat and the restructuring period that followed to preserve the company's financial situation and, thus, redeploy its activity.

At the end of December 2023, operating income amounted to €36,000 compared to €3.00 million a year earlier. Testifying to the drastic restructuring measures implemented, operating expenses were significantly reduced and amounted to €3.20 million compared to €33.10 million the previous year. Operating profit thus stands at -€3.10 million, compared to -€30.10 million in 2022.

After taking into account a financial result of -0.03 M€ and an exceptional result of -0.04 M€, the net result stands at -3.20 M€ as of December 31, 2023.

At the end of this financial year, the Company's shareholders' equity amounts to €0.43 million, compared to €3.60 million at the end of December 2022. Available cash, which includes a Research Tax Credit of 2. €50 million, is €3.50 million as of December 31, 2023, compared to €10.40 million as of December 31, 2022. Financial debts amount to €2.72 million and correspond to a PGE taken out with BNP and a BPI R & D loan.

### **Redeployment of activity in the field of e-health**

During the 2023 financial year, Quantum Genomics laid the foundations for a new business project to drive and create shareholder value. As indicated to the market, the company has held numerous discussions with unlisted HealthTech companies, meeting specific selection criteria: a major field of activity, an innovative and differentiating project, and know-how that can be replicated internationally, a high-performance team that complements that of Quantum Genomics.

At the end of this process, Quantum Genomics entered into exclusive negotiations on December 13, 2023, with a view to a merger with ExactCure, a French HealthTech developing a device combining artificial intelligence and mathematical modeling, making it possible to simulate the behavior that a drug will have when it is taken by the patient and thus to best adapt the treatment taking, according to the individual characteristics of each patient. This technology, which has a CE mark, is already implemented by major healthcare solution providers and initially targets pharmaceutical laboratories. The resulting entity would thus become one of the first Digital Health companies listed on the Euronext Growth market. This project was the subject of [a detailed press release on December 14, 2023](#).

To successfully complete this merger, Quantum Genomics will submit the operations described below to the vote of its shareholders.

**For this purpose, the Ordinary Annual and Extraordinary General Meeting will be held on April 24, 2024, at 10:00 a.m. at the Cozy Meeting Center, 34 Avenue des Champs-Élysées, 75008 Paris.**

This Meeting will notably be called upon to decide on the following operations:

#### **- the reduction in the share capital of Quantum Genomics:**

The share capital of Quantum Genomics would be decreased from 13,935,691.31 euros to 1,393,569.13 euros. The par value of Quantum Genomics shares, which today is around €0.40 (forty euro cents), would be decreased to around €0.04 (four euro cents).

This reduction would make it possible to partially offset the losses for the year and the "retained earnings" debt item. It would also facilitate the release of capital during future capital increases of the Company.

#### **- the contribution in kind of 100% of ExactCure shares:**

277,031 shares of ExactCure, representing the entirety of the voting rights and capital of ExactCure, would be contributed to Quantum Genomics for a total contribution value of 6,000,000 euros.

As remuneration for their contributions, the contributors would benefit from the issue of 34,854,973 shares of Quantum Genomics for their benefit, to be issued at a unit price of 0.1721418 euros (corresponding to a valuation of the Company of 6,000,000 euros). The issue price of the new shares of Quantum Genomics was established based on the implementation of the Revalued Net Asset Value (RNAV) method, which is based on the determination of the fair value of the various assets and liabilities of the company. This method is also called the "heritage method." The implementation of this method was based in particular on (i) the

reference to comparable financial transactions (takeover of a company without active operational activity, which is listed on the stock exchange) and (ii) other latent assets.

The issue price of the new shares of Quantum Genomics shows a premium of approximately 70% compared to the closing share price on March 11, 2024.

The shareholders of ExactCure and Quantum Genomics signed a contribution agreement relating to the transaction on March 12, 2024.

The report(s) of the contribution auditors ruling on the value of the contributions in kind and the remuneration of the contributions will be made available to shareholders on the Quantum Genomics website.

As a result of these operations, the share capital of Quantum Genomics will be increased to 2,787,137.94 euros divided into 69,709,954 shares. Quantum Genomics shareholders would retain 50% of the Company's capital.

Thus, a shareholder of Quantum Genomics with a 1% holding in the capital of Quantum Genomics before the operation (based on the share capital of 13,935,691.31 euros divided into 34,854,981 shares) will have a holding of approximately 0.5% of the capital of Quantum Genomics following the contribution (based on a share capital of 2,787,137.94 euros divided into 69,709,954 shares).

Based on the shareholders' equity as of December 31, 2023, the share of shareholders' equity per share which amounted to approximately 0.012 euros prior to the issue of 34,854,973 shares of Quantum Genomics as remuneration for the contribution, would be approximately 0.092 euro following this issuance, on an undiluted basis.

At the end of the contribution operation, the current directors of ExactCure, Frédéric Dayan, Sylvain Benito, and Fabien Astic, will respectively have 20.21%, 9.02%, and 6.86% of Quantum Genomics's capital. OneRagTime will have 8.54% of the capital, and Otium Capital will hold 5.80% of the capital.

All the preparatory documents for the April 24 Ordinary and Extraordinary General Meeting have been made available to shareholders on the Company's website .

**If the Company's shareholders were to approve the resolutions which will be submitted to their vote, 2024 could mark a new start for Quantum Genomics and the start of an innovative and value-creating project, putting artificial intelligence to the benefit of challenges public health keys.**

## **Contacts**

### **Quantum Genomics**

[contact@quantum-genomics.com](mailto:contact@quantum-genomics.com)

### **Valfa Communication (EUROPE)**

Communication financière et médias

[irquantumgenomics@gmail.com](mailto:irquantumgenomics@gmail.com)